Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

GASPAR N. MARSHALL L.V. BINNER D. HEROLD R. ROUSSEAU R. BLANC P. CAPDEVILLE R. CARLEER J. COPLAND C. KERLOEGUEN Y. NORGA K. PACAUD L. SEVAUX M.A. SPADONI C. ŠTĚRBA Jaroslav LIGAS F. TAUBE T. UTTENREUTHER-FISCHER M. CHIOATO S. O'CONNELL M.A. GEOERGER B. BLAY J.Y. SORIA J.C. KAYE S. WULFF B. BRUGIERES L. VASSAL G. PEARSON ADJ

Year of publication 2018
Type Article in Periodical
Magazine / Source Annals of Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.1093/annonc/mdy002
Doi http://dx.doi.org/10.1093/annonc/mdy002
Keywords PEDIATRIC-PATIENTS; HODGKINS-LYMPHOMA; SOLID TUMORS; YOUNG-ADULTS; ONCOLOGY; CHILDREN; PARTICIPATION; APPROPRIATE; TEENAGERS; RECURRENT
Description The impressive progress recently observed in adult cancers through the introduction of new drugs has not yet been translated to adolescents 12-17 years of age [defined according to the International Conference on Harmonization (ICH) E11]. The current drug development landscape separates adult and paediatric drug development (Table 1). Adolescents are grouped with children, leading to a mismatch with a lack of trials for adolescents with relapsed cancer and delayed access to new, effective drugs already available for adults.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.